F. Hoffmann-La Roche — Genentech
Tracked across 17 events · 132 articles · First seen Dec 19, 2025 · Last active Aug 24, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: As a member of the Roche Group, F. Hoffmann-La Roche — Genentech>>> developed giredestrant and had its New Drug Application accepted by the United States — Food and Drug Administration>>> for priority review, indicating potential for a new standard-of-care in breast cancer treatment.
Jun 02, 2026 · 6 articles
Tech
Impact: F. Hoffmann-La Roche — Genentech announced positive Phase II clinical trial data for its obesity drugs, enicepatide and petrelintide, which could significantly strengthen its product portfolio and market position in the obesity treatment sector. The company is advancing both drugs to Phase III development and initiating a combination trial.
May 27, 2026 · 19 articles
Business
F. Hoffmann-La Roche — Genentech, a member of the Roche Group, held a topping out ceremony on August 18, 2026, marking the completion of the structural framework of its new biomanufacturing facility in United States…
Impact: F. Hoffmann-La Roche — Genentech is the primary actor, celebrating the topping out of its new $2 billion facility in United States — Holly Springs, which will produce metabolic treatments and strengthen its U.S. manufacturing footprint.
Aug 18, 2026 · 6 articles
Business
On August 24, 2026, Hanmi Pharm announced an exclusive licensing agreement with F. Hoffmann-La Roche — Genentech, a member of the Roche Group, for the worldwide development, manufacturing, and commercialization of HM17321, a novel UCN2…
Impact: F. Hoffmann-La Roche — Genentech gains exclusive rights to a promising obesity therapy, expanding its pipeline. The deal involves significant financial commitment but offers potential long-term returns.
Jul 20, 2026 · 7 articles
Business
Impact: F. Hoffmann-La Roche — Genentech gains access to MaxCyte's platform technologies to advance its cell therapy pipeline, potentially accelerating development timelines. The partnership is a strategic move to strengthen its cell therapy capabilities.
Jul 21, 2026 · 6 articles
Regulatory
Impact: F. Hoffmann-La Roche — Genentech, Roche's US unit, is one of the nine major pharmaceutical companies that signed deals with the Donald Trump administration to reduce drug prices.
Dec 19, 2025 · 7 articles
Regulatory
Impact: F. Hoffmann-La Roche — Genentech's Tecentriq (atezolizumab) is the therapy guided by Signatera in this CDx application. Positive trial data could boost Tecentriq's use in adjuvant bladder cancer.
Aug 05, 2026 · 7 articles
Tech
Impact: Provided funding and data from the ORATORIO trial; the method could help evaluate Ocrelizumab's effect on cortical lesions.
Jul 07, 2026 · 6 articles
Business
Impact: F. Hoffmann-La Roche — Genentech has licensed MiNK Therapeutics' STAC-BBB platform for neurological targets, indicating a past business relationship that could be affected by Sangamo's strategic review.
Jun 08, 2026 · 7 articles
Tech
Impact: One of the funders; may be associated with lung cancer treatments.
Jul 13, 2026 · 6 articles
Regulatory
Mapp Biopharmaceutical Co., Ltd. (ArkBio) announced that the U.S. United States — Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II clinical trial in severely ill RSV-infected infants, including those in…
Impact: F. Hoffmann-La Roche — Genentech, as a partner of ArkBio, may benefit from the progress of ziresovir through their strategic collaboration.
Jul 20, 2026 · 6 articles
Business
Impact: Gavin Barnard previously held senior leadership roles at F. Hoffmann-La Roche — Genentech, contributing to his extensive biopharma experience.
Apr 16, 2026 · 6 articles
Business
Impact: F. Hoffmann-La Roche — Genentech's Ocrevus faces potential biosimilar competition, which may erode market share.
Jul 09, 2026 · 14 articles
Business
Impact: F. Hoffmann-La Roche — Genentech is mentioned as Borellini's former employer; not directly affected by this event.
Jul 13, 2026 · 6 articles
Business
Helfie AI, an AI-powered preventative healthcare platform, announced the appointment of Patrick Gates and Sunita Parasuraman as Non-Executive Directors. Patrick Gates, a former Apple and Airbnb executive with over three decades of engineering leadership, previously…
Impact: F. Hoffmann-La Roche — Genentech is mentioned as a former employer of Sunita Parasuraman, providing background but not directly affected.
Jul 20, 2026 · 6 articles
Tech
Impact: F. Hoffmann-La Roche — Genentech is a fully owned subsidiary of Roche in the United States. This event does not directly impact F. Hoffmann-La Roche — Genentech.
Jun 29, 2026 · 7 articles
100
Hanmi Pharm signed licensing agreement F. Hoffmann-La Roche — GenentechHanmi Pharm Genentech...
90
F. Hoffmann-La Roche — Genentech raised final beamGenentech tops out Holly...
80
F. Hoffmann-La Roche — Genentech paid upfront Hanmi PharmHanmi Pharm Genentech...
ERGEN INTELLIGENCE
Track F. Hoffmann-La Roche — Genentech live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard